EPIGENOMICS Aktie

>EPIGENOMICS Performance

1 Woche: -10,3%

1 Monat: -14,7%

3 Monate: -3,3%

6 Monate: -3,3%

1 Jahr: -17,1%

laufendes Jahr: -3,3%

>EPIGENOMICS Aktie

Name:

EPIGENOMICS AG NA O.N.

Land:

Deutschland

Sektor:

Gesundheit

ISIN/ Wkn:

DE000A37FT41 / A37FT4

Symbol/ Ticker:

ECX (Frankfurt)

Kürzel:

FRA:ECX, ETR:ECX, ECX:GR

Index:

Webseite:

https://www.epigenomics.c..

Profil:

Epigenomics AG is a molecular diagnostics company focused on transforming cancer testing through advanced blood-based technologies. Headquartered in Berlin, Germany, the company specializes in developing and globally commercializing innovative biomar..
>Volltext..

Marktkapitalisierung:

0.76 Mio. EUR

Unternehmenswert:

0.35 Mio. EUR

Umsatz:

0.02 Mio. EUR

EBITDA:

Nettogewinn:

-0.31 Mio. EUR

Gewinn je Aktie:

-0.35 EUR

Schulden:

Liquide Mittel:

0.42 Mio. EUR

Operativer Cashflow:

Bargeldquote:

Umsatzwachstum:

Gewinnwachstum:

91.05%

Dividende je Aktie:

Dividendenrendite:

Dividendenschätzung:

Insiderhandel:

Suchwörter:

EPIGENOMICS

Letzte Datenerhebung:

04.04.26

>EPIGENOMICS Kennzahlen

Aktien/ Unternehmen:

Aktien: 0.88 Mio. St.

Frei handelbar: 85%

Leerverk. Aktien: -

Rückkaufquote: -

Mitarbeiter: -

Umsatz/Mitarb.: -

Analysten:

Analystenrating: No rating

Kursziel: -

Bewertung:

KGV: -

KGV lG: -

KUV: -

KBV: -

PEG-Ratio: -

EV/EBITDA: -

Rentabilität:

Bruttomarge: -

Gewinnmarge: -1250%

Operative Marge: -1695.83%

Managementeffizenz:

Gesamtkaprendite: -

Eigenkaprendite: -

>EPIGENOMICS Peer Group

Gesundheit, Onkologie/ Krebs- Behandlung

>EPIGENOMICS Chart & Kurs - Stuttgart

>EPIGENOMICS News

25.02.26 - 15:18	Illumina partners go beyond the genome, driving cancer breakthroughs using spatial transcriptomics, epigenomics, and proteomics (PR Newswire)
	At AGBT, researchers reveal new findings from studies leveraging Illumina's multiomics solutions SAN DIEGO, Feb. 25, 2026 /PRNewswire/ -- Illumina, Inc. (NASDAQ: ILMN) today announced new customer breakthroughs in oncology powered by Illumina's spatial transcriptomics, 5-base sequencing,......

23.02.26 - 18:03	New Gentle Methyl Conversion Kit Delivers High-Accuracy Profiling from as Little as 100 pg of DNA (PR Newswire)
	New commercial kit brings Nature Communications-validated methylation analysis chemistry to researchers working with low-input and cfDNA samples CAMBRIDGE, Mass., Feb. 23, 2026 /PRNewswire/ -- Ellis Bio, a developer of next-generation epigenomics technologies, today announced the official......

05.09.25 - 19:45	PACB Partners With EpiCypher to Advance Epigenomics Using Fiber-Seq (Zacks)
	PacBio collaborates with EpiCypher to integrate Fiber-Seq and HiFi sequencing, advancing single-molecule epigenomics with new chromatin mapping tools....

03.09.25 - 15:09	PacBio and EpiCypher Partner to Deliver Novel Insights into Epigenomics with Fiber-seq Workflow (GlobeNewswire EN)
	New addition to PacBio Compatible program enables scientists to connect genetic variation with gene regulation in a single assay, advancing research in rare disease and cancer New addition to PacBio Compatible program enables scientists to connect genetic variation with gene regulation in a single assay, advancing research in rare disease and cancer...

10.07.25 - 17:06	Vorläufiges Halbjahresergebnis zum 30. Juni 2025 (Pressetext)
	Um den gesamten Artikel unter adhoc.pressetext.com zu lesen, klicken Sie bitte auf die Überschrift...

28.04.25 - 10:21	Vorabbekanntmachung Finanzberichte News: Epigenomics AG (EQS)
	Um den gesamten Artikel unter eqs-news.com zu lesen, klicken Sie bitte auf die Überschrift...

23.04.25 - 11:33	Ad-hoc News: Epigenomics AG (EQS)
	Epigenomics AG: Jahresergebnis zum 31. Dezember 2024 und Prognoseabweichung...

10.04.25 - 14:03

Signios Bio Launches with AI-Driven Bioinformatics and Advanced Multiomics Platform to Power the Future of Precision Medicine and Drug Discovery (Business Wire)

FOSTER CITY, Calif.--(BUSINESS WIRE)--Signios Biosciences ("Signios Bio"), a science-first biotechnology company at the forefront of multiomics and AI-powered bioinformatics, today announced its rebranding from its previous identity as the US based research division of MedGenome Inc. This milestone marks a new era, better positioning the brand in the US on its mission of long-term partnership with researchers to accelerate precision medicine and drug discovery. A New Brand with a Bold Vision With a focus on scientific collaboration and breakthrough discovery, Signios Bio offers an integrated end-to-end suite of multiomic technologies, including genomics, transcriptomics, proteomics, epigenomics, metabolomics, microbiomics, and spatial biology—all powered by a proprietary, AI-driven bioinformatics platform. This comprehensive capability empowers pharmaceutical companies, biotech firms, and academic institutions to decode complex disease biology, identify novel biomarkers, and drive forward targ...

>Impressum >Über uns >Datenschutz >Financial Data & Solutions

>Behalte deine Investments mit realtime Kursen & News im Blick. Finde neue spannende Aktien! Registriere Dich und werde Mitglied!

Zitat des Tages: Notwendigkeit ist bei weitem stärker als die Kunst. - Aischylos

Partner: >TradegateBSX Börse | >Dukascopy | >TradingView | >Boersentreff- Partner

Börsentreff auf Facebook |

Börsentreff auf X |

Börsentreff auf Instagram